-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3916 HT-6184 Inhibits the Formation of the NLRP3 Inflammasome in Human Monocytic THP-1 Cells

Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Hematology Disease Topics & Pathways:
Research, Translational Research, assays, drug development, immune mechanism, Therapies, immunology, Biological Processes, molecular biology, Technology and Procedures, imaging, molecular testing
Monday, December 11, 2023, 6:00 PM-8:00 PM

Benjamin Bearss, MS*, Devan Bursey, MS*, Taylor Avei*, Alexis Mollard, PhD*, Jared Bearss, MBA*, Margit Maria Janat-Amsbury, MD, PhD and David J. Bearss, PhD

Halia Therapeutics, Lehi, UT

Background

The NLRP3 inflammasome is a multiprotein complex composed of several proteins, including NLRP3, ASC, Nek-7, and pro-caspase-1. Many immune cell populations express the NLRP3 inflammasome. In the presence of various exogenous stimuli such as lipopolysaccharide (LPS) or extracellular ATP, the NLRP3 inflammasome components assemble and become activated, releasing pro-inflammatory cytokines IL-1β and IL-18. One of the critical steps in inflammasome assembly is the recruitment of ASC and the formation of ASC protein aggregates called specks. These specks are large enough to be measured through microscopy, and the ASC speck count indicates NLRP3 activation. The release of IL-1β and IL-18 and the upregulation of NLRP3 inflammasome component genes have been observed in many inflammatory and hematological disorders, suggesting the NLRP3 pathway is involved in the disease pathogenesis of many diseases.

Purpose

HT-6184 is a small molecule that blocks the assembly of the NLRP3 inflammasome through allosteric binding to the protein Nek7. Here we demonstrate the ability of HT-6184 to modulate NLRP3 inflammasome formation by measuring ASC specks using a human monocytic THP-1 cell line engineered to express a GFP-labeled ASC protein.

Methods

THP1-ASC-GFP cells were cultured in RPMI 1640 with 10% heat-inactivated FBS, 100 μg/mL normocin, and 100 μg/mL Pen-Strep. Cells were seeded at 400,000 cells per well in a 96-well plate and left overnight. Cells were then treated with vehicle or LPS for 3 hours. Following LPS stimulation, cells were treated with vehicle or HT-6184 for 2 hours. After incubation, cells were treated with 5 μM Nigericin and imaged in 3-minute intervals for 1 hour. The images were analyzed for specks.

Results

By treating THP1-ASC-GFP with LPS and nigericin, we induced the formation of ASC specks and visualized them using fluorescent microscopy. Cells treated with 200 nM HT-6184 had significantly fewer ASC specks than the LPS and nigericin-treated control. ASC speck inhibition by HT-6184 was dose-dependent, as inhibition of speck formation decreased with lower doses of HT-6184.

Conclusions

HT-6184 effectively prevents the formation of ASC specks in THP-1-ASC-GFP cells. Since THP-1 cells are a monocytic cell line, this data suggests our ability to inhibit the NLRP3 pathway in hematological disorders effectively. By preventing inflammasome formation and activation, we expect to be able to reduce disease burden in hematological diseases.

Disclosures: Bearss: Halia Therapeutics: Current Employment, Current holder of stock options in a privately-held company. Bursey: Halia Therapeutics: Current holder of stock options in a privately-held company. Avei: Halia Therapeutics: Current holder of stock options in a privately-held company. Mollard: Halia Therapeutics: Current Employment, Current holder of stock options in a privately-held company. Bearss: Halia Therapeutics: Current Employment, Current holder of stock options in a privately-held company. Janat-Amsbury: Halia Therapeutics: Current Employment, Current holder of stock options in a privately-held company. Bearss: Halia Therapeutics: Current Employment, Current holder of stock options in a privately-held company.

*signifies non-member of ASH